A healthcare professional can assess your symptoms, discuss potential causes and advise whether further investigation or treatment may be required
Clinical Data Clinical Trial Results 22.5% Average Weight Loss 72 weeks 89% Achieved 5%+ Loss of participants 2,539 Trial Participants SURMOUNT-1 Data from SURMOUNT-1 Phase 3 clinical trial, published in The New England Journal of Medicine
Patients with a history of chronic or recurrent genitourinary infections are more likely to develop genitourinary infections when using SYNJARDY or SYNJARDY XR
But if you are taking a glucagon-like peptide-1 drug better known as GLP-1 for weight loss, the protocol for getting back on track may be different from missing a dose of antibiotics
Patient support
This peptide combo may benefit: Adults over age 40 with declining GH levels Individuals with visceral fat despite good diet/exercise Patients recovering from surgery, injury, or muscle wasting People with early signs of aging who want regenerative support Those with non-alcoholic fatty liver disease or high cardiometabolic risk If results havent matched expectations, this is usually why